Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration (NCT05657301)
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
🩺 Plain-English Summary (8th-Grade Level)
VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector. The standard of care for patients with neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and reduction in fluid. A one time placement of a product which inhibits VEGF has the potential to reduce the patient burden of regular intraocular injections.
Who can join: Review the eligibility criteria below.
Location: Kanghong Investigative Site — Phoenix, Arizona
Age range: 50 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Kanghong Investigative Site — Phoenix, Arizona
- Kanghong Investigative Site — Lemont, Illinois
- Kanghong Investigative Site — Boston, Massachusetts
- Kanghong Investigative Site — Reno, Nevada
- Kanghong Investigative Site — Cherry Hill, New Jersey
- Kanghong Investigative Site — Germantown, Tennessee
- Kanghong Investigative Site — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Age-Related Macular Degeneration
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders — Springfield, Illinois
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration — San Francisco, California
- ForeseeHome NRich Registry — Toms River, New Jersey
- Impact of Non-Exudative Type 1 MNV on AMD Progression — Salt Lake City, Utah
- A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
- Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration — Scottsdale, Arizona
Explore by condition: All Age-Related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.